R. A. Seder and S. Gurunathan. DNA vaccines-designer vaccines for the 21st century. N. Engl. J. Med.
R. Wang, D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, J. Sedegah, C. de Taisne, J. A. Norman, and S. L. Hoffman. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science
S. Calarota, G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom, and B. Wahren. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet
J. Schneider, S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med.
N. J. Sullivan, A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. Development of a preventive vaccine for Ebola virus infection in primates. Nature
R. R. Amara, F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science
G. Ramon. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur
F. R. Vogel and M. F. Powell. A compendium of vaccine adjuvants and excipients. In M. F. Powell and M. J. Newman (eds.), Vaccine Design: The Subunit and Adjuvant Approach Plenum Press, New York, 1995 pp. 141–228.
R. K. Gupta. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev.
E. H. Relyveld, B. Bizzini, and R. K. Gupta. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine
R. K. Gupta, A. C. Chang, P. Griffin, R. Rivera, and G. R. Siber. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine
M. Ulanova, A. Tarkowski, M. Hahn-Zoric, L. A. Hanson, and P. Moingeon. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immunol.
Y. Shi. H. HogenEsch, F. E. Regnier, and S. L. Hem. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine
R. Edelman. Adjuvants for the future. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.), New Generation Vaccines Marcel Dekker, Inc., New York, 1997 pp. 173–192.
R. M. Zinkernagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev.
P. Bretscher and M. Cohn. A theory of self-nonself discrimination. Science
C. A. Janeway, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp. on Quant. Biol.
54 Pt 1 C:1–13 (1989).
R. Medzhitov and C. A. Janeway, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell
P. Matzinger. Tolerance, danger, and the extended family. Annu. Rev. Immunol.
P. Matzinger. An innate sense of danger. Semin. Immunol.
Y. Shi, W. Zheng, K. L. Rock, H. HogenEsch, F. E. Regnier, and S. L. Hem. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA
D. T. Fearon. Seeking wisdom in innate immunity. Nature
D. T. Fearon and R. M. Locksley. The instructive role of innate immunity in the acquired immune response. Science
H. C. Yip, A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol.
G. L. Gustafson and M. J. Rhodes. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol.
J. T. Ulrich and K. R. Myers. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions. Pharm. Biotechnol.
J. T. Ulrich. MPLr immunostimulant: adjuvant formulations. In D. T. O'Hagan (ed.), Vaccine Adjuvants: Preparation Methods and Research Protocols. Humana Press Inc., Totowa, New Jersey, 2000 pp. 273–282.
S. Thoelen, P. Van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoui, and A. Meheus. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine
A. W. Wheeler, J. S. Marshall, and J. T. Ulrich. A Th1-inducing adjuvant, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol.
D. A. Johnson, D. S. Keegan, C. G. Sowell, M. T. Livesay, C. L. Johnson, L. M. Taubner, A. Harris, K. R. Myers, J. D. Thompson, G. L. Gustafson, M. J. Rhodes, J. T. Ulrich, J. R. Ward, Y. M. Yorgensen, J. L. Cantrell, V. G. Brookshire, and P. Moingeon. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem.
L. D. Hawkins, S. T. Ishizaka, P. McGuinness, H. Zhang, W. Gavin, B. DeCosta, Z. Meng, H. Yang, M. Mullarkey, D. W. Young, D. P. Rossignol, A. Nault, J. Rose, M. Przetak, J. C. Chow, and F. Gusovsky. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther.
S. Sasaki, T. Tsuji, K. Hamajima, J. Fukushima, N. Ishii, T. Kaneko, K. Q. Xin, H. Mohri, I. Aoki, T. Okubo, K. Nishioka, and K. Okuda. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immunol.
N. K. Childers, K. L. Miller, G. Tong, J. C. Llarena, T. Greenway, J. T. Ulrich, S. M. Michalek, and P. Moingeon. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immunol.
J. P. Messina, G. S. Gilkeson, and D. S. Pisetsky. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol.
T. Tokunaga, H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, and T. Sudo. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. Infection and Immunity
A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature
A. P. Bird. CpG islands as gene markers in the vertebrate nucleus. Trends Genet.
H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, S. Akira, and P. Moingeon. A Toll-like receptor recognizes bacterial DNA. Nature
T. Sparwasser, E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol.
D. M. Klinman, K. M. Barnhart, and J. Conover. CpG motifs as immune adjuvants. Vaccine
M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D. T. O'Hagan. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res.
D. Broide, J. Schwarze, H. Tighe, T. Gifford, M. D. Nguyen, S. Malek, J. Van Uden, E. Martin-Orozco, E. W. Gelfand, and E. Raz. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol.
G. Hartmann, R. D. Weeratna, Z. K. Ballas, P. Payette, S. Blackwell, I. Suparto, W. L. Rasmussen, M. Waldschmidt, D. Sajuthi, R. H. Purcell, H. L. Davis, and A. M. Krieg. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol.
C. R. Kensil. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst.
A. M. Glaueri, J. T. Dingle, and J. A. Lucy. Action of saponins on biologic membranes. Nature
C. R. Kensil and R. Kammer. QS-21: a water-soluble triterpene glycoside adjuvant. Exp. Opin. Invest. Drugs
T. G. Evans, M. J. McElrath, T. Matthews, D. Montefiori, K. Weinhold, M. Wolff, M. C. Keefer, E. G. Kallas, L. Corey, G. J. Gorse, R. Belshe, B. S. Graham, P. W. Spearman, D. Schwartz, M. J. Mulligan, P. Goepfert, P. Fast, P. Berman, M. Powell, D. Francis, M. L. Clements-Mann, N. Verani-Ketter, S. Erb, C. M. Smith, R. B. Belshe, L. J. Wagner, D. H. Schwartz, and P. Moingeon. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans. Vaccine
D. C. Waite, E. W. Jacobson, F. A. Ennis, R. Edelman, B. White, R. Kammer, C. Anderson, and C. R. Kensil. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine
S. Sasaki, K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol.
A. W. Heath. Cytokines as immunologic adjuvants. In M. F. Powell and M. J. Newman, (eds.), Vaccine Design: The Subunit and Adjuvant Approach Plenum Press, New York, 1995 pp. 645–658.
M. L. Salgaller and P. A. Lodge. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol.
A. C. Allison and N. E. Byars. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods
E. B. Lindblad. Freund's Adjuvants. In D. O'Hagan (ed.), Vaccine Adjuvants: Preparation methods and research protocols Humana Press, Totowa, New Jersey, 2000 pp. 49–64.
G. Ott, G. L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In M. F. Powell and M. J. Newman (eds.), Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, 1995 pp. 277–296.
D. M. Cataldo and G. Van Nest. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine
D. A. Higgins, J. R. Carlson, and G. Van Nest. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine
D. T. O'Hagan, G. S. Ott, and G. Van Nest. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today
P. Traquina, M. Morandi, M. Contorni, and G. Van Nest. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis.
T. Menegon, V. Baldo, C. Bonello, C. D. Dalla, A. Di Tommaso, and R. Trivello. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur. J. Epidemiol.
S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, and A. Podda. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine
J. Nicholson. Trade systems in less-developed countries. Lancet
T. C. Heineman, M. L. Clements-Mann, G. A. Poland, R. M. Jacobson, A. E. Izu, D. Sakamoto, J. Eiden, G. A. Van Nest, and H. H. Hsu. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine
D. M. Granoff, Y. E. McHugh, H. V. Raff, A. S. Mokatrin, and G. A. Van Nest. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immunol.
R. F. Pass, A. M. Duliege, S. Boppana, R. Sekulovich, S. Percell, W. Britt, and R. L. Burke. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis.
S. Nitayaphan, C. Khamboonruang, N. Sirisophana, P. Morgan, J. Chiu, A. M. Duliege, C. Chuenchitra, T. Supapongse, K. Rungruengthanakit, M. deSouza, J. R. Mascola, K. Boggio, S. Ratto-Kim, L. E. Markowitz, D. Birx, V. Suriyanon, J. G. McNeil, A. E. Brown, R. A. Michael. A phase I/II trial of HIV SF2 gp120/ MF59 vaccine in seronegative Thais. Vaccine
J. O. Kahn, F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis.
A. G. Langenberg, R. L. Burke, S. F. Adair, R. Sekulovich, M. Tigges, C. L. Dekker, and L. Corey. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity. Ann. Intern. Med.
C. K. Cunningham, D. W. Wara, M. Kang, T. Fenton, E. Hawkins, J. McNamara, L. Mofenson, A. M. Duliege, D. Francis, E. J. McFarland, and W. Borkowsky. Safety of 2 recombinant human immunodeficiency virus type 1 (hiv-1) envelope vaccines in neonates born to hiv-1-infected women. Clin. Infect. Dis.
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis.
S. Cherpelis, I. Srivastava, A. Gettie, X. Jin, D. D. Ho, S. W. Barnett, and L. Stamatatos. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/ human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J. Virol.
I. T. Ling, S. A. Ogun, P. Momin, R. L. Richards, N. Garcon, J. Cohen, W. R. Ballou, and A. A. Holder. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine
J. A. Stoute, M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, and M. Marchand. A preliminary evaluation of a recombinant circum-sporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med.
S. McCormack, A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry, G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J. Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, and J. Weber. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine
G. W. Lawrence, A. Saul, A. J. Giddy, R. Kemp, D. Pye, M. Ulanova, A. Tarkowski, M. Hahn-Zoric, L. A. Hanson, and P. Moingeon. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine
J. Aucouturier, V. Ganne, and A. Laval. Efficacy and safety of new adjuvants. Ann. N. Y. Acad. Sci.
A. Gringeri, E. Santagostino, M. Muca-Perja, P. M. Mannucci, J. F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R. C. Gallo, and D. Zagury. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J. Hum. Virol.
H. Toledo, A. Baly, O. Castro, S. Resik, J. Laferte, F. Rolo, L. Navea, L. Lobaina, O. Cruz, J. Miguez, T. Serrano, B. Sierra, L. Perez, M. E. Ricardo, M. Dubed, A. L. Lubian, M. Blanco, J. C. Millan, A. Ortega, E. Iglesias, E. Penton, Z. Martin, J. Perez, M. Diaz, and C. A. Duarte. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine
B. Genton, F. Al-Yaman, R. Anders, A. Saul, G. Brown, D. Pye, D. O. Irving, W. R. Briggs, A. Mai, M. Ginny, T. Adiguma, L. Rare, A. Giddy, R. Reber-Liske, D. Stuerchler, and M. P. Alpers. Safety and immunogenicity of a three-component bloodstage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine
C. R. Alving. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta
G. Gregoriadis. Immunologic adjuvants: a role for liposomes. Immunol. Today
F. Ambrosch, G. Wiedermann, S. Jonas, B. Althaus, B. Finkel, R. Gluck, and C. Herzog. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine
D. T. Bungener, A. Huckriede, and J. Wilschut. Virosomes as an antigen delivery system. J. Liposome Res.
L. Krishnan, C. J. Dicaire, G. B. Patel, and G. D. Sprott. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immunol.
J. W. Conlan, L. Krishnan, G. E. Willick, G. B. Patel, and G. D. Sprott. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine
B. Guy, N. Pascal, A. Francon, A. Bonnin, S. Gimenez, E. Lafay-Vialon, E. Trannoy, and J. Haensler. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine
J. M. Muderhwa, G. R. Matyas, L. E. Spitler, and C. R. Alving. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J. Pharm. Sci.
S. Gould-Fogerite, M. T. Kheiri, F. Zhang, Z. Wang, A. J. Scolpino, E. Feketeova, M. Canki, and R. J. Mannino. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev.
H. Chen, V. Torchilin, and R. Langer. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. J. Control. Release
I. G. Barr, A. Sjolander, and J. C. Cox. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev.
G. F. Rimmelzwaan, M. Baars, R. van Beek, G. van Amerongen, K. Lovgren-Bengtsson, E. C. Claas, and A. D. Osterhaus. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. Vaccine
78(Pt 4):757–765 (1997).
F. A. Ennis, J. Cruz, J. Jameson, M. Klein, D. Burt, and J. Thipphawong. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology
S. Soltysik, J. Y. Wu, J. Recchia, D. A. Wheeler, M. J. Newman, R. T. Coughlin, and C. R. Kensil. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine
R. E. Smith, A. M. Donachie, D. Grdic, N. Lycke, and A. M. Mowat. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol.
D. L. Emery, J. S. Rothel, and P. R. Wood. Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes. Immunol. Cell Biol.
68 (Pt 2):127–136 (1990).
E. J. Verschoor, P. Mooij, H. Oostermeijer, M. van der Kolk, P. ten Haaft, B. Verstrepen, Y. Sun, B. Morein, L. Akerblom, D. H. Fuller, S. W. Barnett, and J. L. Heeney. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol.
N. K. Polakos, D. Drane, J. Cox, P. Ng, M. J. Selby, D. Chien, D. T. O'Hagan, M. Houghton, and X. Paliard. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol.
A. Sjolander, D. Drane, E. Maraskovsky, J. Scheerlinck, A. Suhrbier, J. Tennent, and M. Pearse. Immune responses to ISCOM((R)) formulations in animal and primate models. Vaccine
J. Bates, J. Ackland, A. Coulter, J. Cox, D. Drane, R. Macfarlan, J. Varigos, T.-Y. Wong, and W. Woods. IscomT adjuvant-a promising adjuvant for influenza virus vaccines. In L. E. Brown, A. W. Hampson, and R. G. Webster (eds.), Options for the Control of Influenza III Elsevier Science B.V., Amsterdam, 1996 pp. 661–667.
K. Lovgren-Bengtsson and B. Morein. The ISCOMTM Technology. In D. O'Hagan (ed.), Vaccine Adjuvants: Preparation Methods and Research Protocols Humana Press, Totowa, New Jersey, 2000 pp. 239–258.
J. M. Brewer, L. Tetley, J. Richmond, F. Y. Liew, and J. Alexander. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol.
I. Tsunoda, A. Sette, R. S. Fujinami, C. Oseroff, J. Ruppert, C. Dahlberg, S. Southwood, T. Arrhenius, L. Q. Kuang, R. T. Kubo, R. W. Chesnut, and G. Y. Ishioka. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine
D. F. Nixon, C. Hioe, P. D. Chen, Z. Bian, P. Kuebler, M. L. Li, H. Qiu, X. M. Li, M. Singh, J. Richardson, P. Mcgee, T. Zamb, W. Koff, C. Y. Wang, and D. O'Hagan. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine
H. Okada and H. Toguchi. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst.
S. D. Putney and P. A. Burke. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol.
J. H. Eldridge, J. K. Staas, J. A. Meulbroek, T. R. Tice, and R. M. Gilley. Biodegradable and biocompatible poly(DL-lactideco-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immunol.
D. T. O'Hagan, D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, S. S. Davis, and S. J. Challacombe. Biodegradable microparticles as controlled release antigen delivery systems. Immunology
D. T. O'Hagan, H. Jeffery, M. J. Roberts, J. P. McGee, and S. S. Davis. Controlled release microparticles for vaccine development. Vaccine
D. T. O'Hagan, H. Jeffery, and S. S. Davis. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine
K. J. Maloy, A. M. Donachie, D. T. O'Hagan, and A. M. Mowat. Induction of mucosal and systemic immune responses by immu-nization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology
A. Moore, P. McGuirk, S. Adams, W. C. Jones, J. P. McGee, D. T. O'Hagan, and K. H. Mills. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine
M. L. Hedley, J. Curley, and R. Urban. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med.
M. Singh, M. Briones, G. Ott, and D. O'Hagan. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA.
M. Briones, M. Singh, M. Ugozzoli, J. Kazzaz, S. Klakamp, G. Ott, and D. O'Hagan. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res.
D. O'Hagan, M. Singh, M. Ugozzoli, C. Wild, S. Barnett, M. Chen, G. R. Otten, and J. B. Ulmer. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol.
K. S. Denis-Mize, M. Dupuis, M. L. MacKichan, M. Singh, D. O'Hagan, J. B. Ulmer, J. Donnelly, D. MacDonald, and G. S. Ott. Plasmid DNA adsorbed onto PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther.
J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D. T. O'Hagan. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release
D. T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, K. Higgins, T. C. VanCott, and G. Ott. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine
D. T. O'Hagan. Prospects for the development of new and improved vaccines through the use of microencapsulation technology. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (eds.), New Generation Vaccines Marcel Dekker, Inc., New York, 1997 pp. 215–228.
D. T. O'Hagan, M. Singh, and R. K. Gupta. Poly(lactide-coglycolide) microparticles for the development of single-dose controlled-release vacccines. Adv. Drug Deliv. Rev.
P. Johansen, F. Estevez, R. Zurbriggen, H. P. Merkle, R. Gluck, G. Corradin, and B. Gander. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine
M. J. Newman, M. Balusubramanian, and C. W. Todd. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev.
L. G. Payne, S. A. Jenkins, A. L. Woods, E. M. Grund, W. E. Geribo, J. R. Loebelenz, A. K. Andrianov, and B. E. Roberts. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine
P. Valenzuela, A. Medina, W. J. Rutter, G. Ammerer, and B. D. Hall. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature
R. Schirmbeck, W. Bohm, K. Ando, F. V. Chisari, and J. Reimann. Nucleic-acid vaccination primes hepatitis-b virus surface antigen-specific cytotoxic t-lymphocytes in nonresponder mice. J. Virol.
S. C. Gilbert. Virus-like particles as vaccine adjuvants. In D. O'Hagan (ed.), Vaccine Adjuvants: Preparation methods and research protocols Humana Press, Totowa, New Jersey, 2000 pp. 197–210.
S. C. Gilbert, M. Plebanski, S. J. Harris, C. E. Allsopp, R. Thomas, G. T. Layton, and A. V. Hill. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol.
L. S. Klavinskis, L. A. Bergmeier, L. Gao, E. Mitchell, R. G. Ward, G. Layton, R. Brookes, N. J. Meyers, and T. Lehner. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J. Immunol.
S. J. Martin, A. Vyakarnam, R. Cheingsong-Popov, D. Callow, K. L. Jones, J. M. Senior, S. E. Adams, A. J. Kingsman, P. Matear, and F. M. Gotch. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses. AIDS
M. M. Levine and G. Dougan. Optimism over vaccines administered via mucosal surfaces. Lancet
S. J. Challacombe, D. Rahman, H. Jeffery, S. S. Davis, and D. T. O'Hagan. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology
S. J. Challacombe, D. Rahman, and D. T. O'Hagan. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine
J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release
D. T. O'Hagan. Microparticles as oral vaccines. In D. T. O'Hagan (ed.), Novel Delivery Systems for Oral Vaccines CRC Press, Inc., Boca Raton, 1994 pp. 175–205.
E. S. Cahill, D. T. O'Hagan, L. Illum, A. Barnard, K. H. Mills, and K. Redhead. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine
D. H. Jones, B. W. McBride, C. Thornton, D. T. O'Hagan, A. Robinson, and G. H. Farrar. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect. Immunol.
R. Shahin, M. Leef, J. Eldridge, M. Hudson, and R. Gilley. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immunol.
M. A. Conway, L. Madrigal-Estebas, S. McClean, D. J. Brayden, and K. H. Mills. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine
J. A. Whittum-Hudson, L. L. An, W. M. Saltzman, R. A. Prendergast, and A. B. MacDonald. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat. Med.
K. Allaoui-Attarki, S. Pecquet, E. Fattal, S. Trolle, E. Chachaty, P. Couvreur, and A. Andremont. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-coglycolide) microspheres. Infect. Immunol.
P. A. Marx, R. W. Compans, A. Gettie, J. K. Staas, R. M. Gilley, M. J. Mulligan, G. V. Yamschikov, D. Chen, and J. H. Eldridge. Protection against vaginal SIV transmission with microencapsulated vaccine. Science
J. Tseng, J. L. Komisar, R. N. Trout, R. E. Hunt, J. Y. Chen, A. J. Johnson, L. Pitt, and D. L. Ruble. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect. Immunol.
M. Ugozzoli, D. T. O'Hagan, and G. S. Ott. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology
D. H. Jones, S. Corris, S. McDonald, J. C. Clegg, and G. H. Farrar. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine
E. Mathiowitz, J. S. Jacob, Y. S. Jong, G. P. Carino, D. E. Chickering, P. Chaturvedi, C. A. Santos, K. Vijayaraghavan, S. Montgomery, M. Bassett, and C. Morrell. Biologically erodable microspheres as potential oral drug delivery systems. Nature
D. T. O'Hagan. The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anat.
189(Pt 3):477–482 (1996).
J. E. Eyles, I. D. Spiers, E. D. Williamson, and H. O. Alpar. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J. Pharm. Pharmacol.
D. O'Hagan. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev.
S. M. Michalek, D. T. O'Hagan, S. Gould-Fogerite, G. F. Rimmelzwaan, and A. D. M. E. Osterhaus. Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and ISCOMS. In P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstrock, and J. R. McGhee (eds.), Mucosal Immunology Academic Press, San Diego, 1999 pp. 759–778.
D. J. Brayden. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci.
B. L. Dickinson and J. D. Clements. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immunol.
G. Douce, C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA
G. Douce, M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immunol.
A. Di Tommaso, G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immunol.
V. Giannelli, M. R. Fontana, M. M. Giuliani, D. Guangcai, R. Rappuoli, and M. Pizza. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immunol.
M. M. Giuliani, G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp. Med.
M. Marchetti, M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dougan, R. Rappuoli, and P. Ghiara. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine
J. D. Barackman, G. Ott, S. Pine, D. T. O'Hagan, D. Campoccia, P. Doherty, M. Radice, P. Brun, G. Abatangelo, and D. F. Williams. Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization. Clin. Diagn. Lab. Immunol.
G. Douce, V. Giannelli, M. Pizza, D. Lewis, P. Everest, R. Rappuoli, and G. Dougan. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immunol.
R. Rappuoli, M. Pizza, G. Douce, and G. Dougan. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today
E. J. Ryan, E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immunol.
H. Jakobsen, D. Schulz, M. Pizza, R. Rappuoli, and I. Jonsdottir. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immunol.
D. O'Hagan, C. Goldbeck, M. Ugozzoli, G. Ott, R. L. Burke, P. L. Heritage, M. A. Brook, B. J. Underdown, and M. R. McDermott. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine
C. P. Simmons, P. Mastroeni, R. Fowler, M. Ghaem-maghami, N. Lycke, M. Pizza, R. Rappuoli, and G. Dougan. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol.
J. A. Neidleman, G. Ott, and D. O'Hagan. Mutant heat-labile enterotoxins as adjuvants for CTL induction. In J. M. Walker (ed.), Methods in Molecular Medicine Humana Press, Totowa, New Jersey, 2000 pp. 327–336.
M. Singh, M. Briones, and D. T. O'Hagan. A novel bioadhesive intranasal delivery system for inactivated influenza vaccine. J. Control. Release
M. Ugozzoli, G. Santos, J. Donnelly, and D. T. O'Hagan. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. coli (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant. J. Infect. Dis.
U. Gluck, J. O. Gebbers, and R. Gluck. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol.
R. Gluck, R. Mischler, P. Durrer, E. Furer, A. B. Lang, C. Herzog, and S. J. Cryz, Jr. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis.
M. Yamamoto, H. Kiyono, S. Yamamoto, E. Batanero, M. N. Kweon, S. Otake, M. Azuma, Y. Takeda, and J. R. Mcghee. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol.
M. C. Gagliardi, F. Sallusto, M. Marinaro, A. Langenkamp, A. Lanzavecchia, and M. T. De Magistris. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol.
G. M. Glenn, M. Rao, G. R. Matyas, and C. R. Alving. Skin immunization made possible by cholera toxin. Nature
G. M. Glenn, D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med.
D. Chen, R. L. Endres, C. A. Erickson, K. F. Weis, M. W. McGregor, Y. Kawaoka, and L. G. Payne. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med.
E. C. Lavelle, G. Grant, A. Pusztai, U. Pfuller, and D. T. O'Hagan. The identification of plant lectins with mucosal adjuvant activity. Immunology
C. O. Tacket, H. S. Mason, G. Losonsky, J. D. Clements, M. M. Levine, and C. J. Arntzen. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med.
L. J. Richter, Y. Thanavala, C. J. Arntzen, and H. S. Mason. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol.
S. E. Straus, L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, and S. F. Adair. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet
B. M. Longenecker, M. Reddish, R. Koganty, and G. D. MacLean. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. NY. Acad. Sci.
B. Agrawal, M. J. Krantz, M. A. Reddish, and B. M. Longenecker. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med.
P. Ghiara, M. Rossi, M. Marchetti, A. Di Tommaso, C. Vindigni, F. Ciampolini, A. Covacci, J. L. Telford, M. T. De Magistris, M. Pizza, R. Rappuoli, and G. Del Giudice. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immunol.
H. L. Weiner. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today
S. Toda, N. Ishii, E. Okada, K. I. Kusakabe, H. Arai, K. Hamajima, I. Gorai, K. Nishioka, and K. Okuda. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology
P. J. Giannasca, J. A. Boden, and T. P. Monath. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect. Immunol.
H. Chen, V. Torchilin, and R. Langer. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res.
N. Foster, M. A. Clark, M. A. Jepson, and B. H. Hirst. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine
N. Hussain, P. U. Jani, and A. T. Florence. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res.
L. C. Agren, L. Ekman, B. Lowenadler, and N. Y. Lycke. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol.
L. C. Agren, L. Ekman, B. Lowenadler, J. G. Nedrud, and N. Y. Lycke. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol.
L. Agren, E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2-and germinal center-promoting effects. J. Immunol.
T. J. Goletz, K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA
H. Cao, D. Agrawal, N. Kushner, N. Touzjian, M. Essex, and Y. Lu. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J. Infect. Dis.